Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report)’s stock price traded down 3.4% during trading on Thursday . The company traded as low as $0.3188 and last traded at $0.3188. 130 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 5,622 shares. The stock had previously closed at $0.33.
Avenue Therapeutics Stock Performance
The firm’s 50-day moving average is $0.34 and its 200-day moving average is $0.38. The firm has a market cap of $1.05 million, a price-to-earnings ratio of 0.02 and a beta of -0.17.
About Avenue Therapeutics
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Recommended Stories
- Five stocks we like better than Avenue Therapeutics
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
